RecruitingNCT05264259
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Sponsor
University Hospital, Strasbourg, France
Enrollment
100 participants
Start Date
Sep 5, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- BK positive
- adult
- ok to participed to research
Exclusion Criteria4
- under guardianship
- under curatorship
- opposed to research
- deprived of liberty
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05264259
Related Trials
Immune Registry for BK in Kidney Transplant Recipients
NCT065389611 location
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient
NCT045427331 location
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT024796981 location
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
NCT051012131 location
R-MVST Cells for Treatment of Viral Infections
NCT051834901 location